Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) T.ATE


Primary Symbol: ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by MrMugsyon Mar 10, 2021 6:19pm
270 Views
Post# 32765999

RE:RE:can't win in the ate market

RE:RE:can't win in the ate market
Actuarial wrote: Anything below $6 is a bargain as you already beat the PP price. Anything below $5? It will disappear within a second with any positive NRs. Any positive NRs we can rely on? A lot! Ph3 346, fast track 352, IND 340, new pipeline for IBD, etc. Any future PP needed? No, as ATE has c$74M cash in bank. The future of ATE is bright and certain. So, my advice is, accumulating more when you can at this price. GLTA longs!


Amen Actuarial.
I'm really liking our position right now.

The strategy seems clear - value generation is underway - working on improving the sales potential so that the sales graph doesn't drop off after 2030.

Bring on the new drugs, bring on the new molecules and show Big Pharma that post 2030 is much better than the years leading up to 2030.  

So much to do but everything seems under control at this point.

Good Luck All - stoked !!!!
<< Previous
Bullboard Posts
Next >>